Metabotropic glutamate receptor 5 neuroimaging in schizophrenia

Akkus, Funda; Treyer, Valerie; Ametamey, Simon M; Johayem, Anass; Buck, Alfred; Hasler, Gregor (2017). Metabotropic glutamate receptor 5 neuroimaging in schizophrenia. Schizophrenia Research, 183, pp. 95-101. Elsevier 10.1016/j.schres.2016.11.008

[img] Text
Akkus_Hasler_2017_mGluR5_schizophrenia.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (687kB)
[img] Text
Schizophrenia_mGluR5_supplement.pdf - Supplemental Material
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (771kB)
[img]
Preview
Text
Schizophrenia_mGluR5_publ.pdf - Accepted Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (159kB) | Preview

The metabotropic glutamate receptor 5 (mGluR5) is a promising drug target for the treatment of schizophrenia. In this study, we compared mGluR5 distribution volume ration (DVR) in subjects with schizophrenia and healthy controls. Given our previous findings, we matched samples for gender, age, and smoking status. Binding to mGluR5 was determined using positron emission tomography and [(11)C]ABP688, which binds to an allosteric site with high selectivity. DVR in the 15 individuals with schizophrenia did not differ from that of the 15 controls. In both groups, smoking was associated with marked global reductions in mGluR5 availability (on average 23.8%). In nonsmoking subjects with schizophrenia, there was a positive correlation between mGluR5 DVR in the medial orbitofrontal cortex and the use of antipsychotic drugs (r=0.9, p=0.019). Because antipsychotic drugs such as clozapine appeared to have indirect effects on mGluR5 signaling, our findings may be clinically relevant. They also provide promising leads for elucidating the high comorbidity between schizophrenia and tobacco addiction. Low mGluR5 DVR in smokers my represent a risk factor for schizophrenia. Alternatively, smoking may counteract the potential upregulation of mGluR5 by antipsychotic drugs.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Translational Research Center
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy
04 Faculty of Medicine > University Psychiatric Services > University Hospital of Psychiatry and Psychotherapy > Healthcare Research

UniBE Contributor:

Akkus, Funda, Hasler, Gregor

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0920-9964

Publisher:

Elsevier

Language:

English

Submitter:

Gregor Hasler

Date Deposited:

23 Feb 2017 14:54

Last Modified:

05 Dec 2022 15:00

Publisher DOI:

10.1016/j.schres.2016.11.008

PubMed ID:

27847228

Uncontrolled Keywords:

Glutamate, Nicotine, Positron, emission, tomography, Schizophrenia, mGluR5

BORIS DOI:

10.7892/boris.92311

URI:

https://boris.unibe.ch/id/eprint/92311

Actions (login required)

Edit item Edit item
Provide Feedback